Horizon Adaptive Platform Trial Evaluating Therapies in RRMM

Status Not yet recruiting

Clinical Trial Summary

This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready and whether accrual in the trial will support another arm. Accrual to an arm will terminate in accord with the arm's appendix to the Master Protocol. The purpose of this proposed structure is to support the recurrent research challenge of efficiently evaluating what is the best therapy for a particular patient.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06171685
Study type	Interventional
Source	Multiple Myeloma Research Consortium
Contact	Jessica Vandermark
Phone	(203) 354-7215
Email	vandermarkj@themmrf.org
Status	Not yet recruiting
Phase	Phase 2
Start date	July 31, 2024
Completion date	July 31, 2030

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04083534` - First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)	Phase 1/Phase 2
Terminated	`NCT02020941` - Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy	Phase 2
Completed	`NCT01775553` - Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib	Phase 2
Completed	`NCT01212952` - Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma	Phase 1/Phase 2
Completed	`NCT01233921` - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	N/A
Terminated	`NCT01078441` - Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant	Phase 2
Completed	`NCT00514137` - Sunitinib in Treating Patients With Relapsed Multiple Myeloma	Phase 2
Completed	`NCT00306813` - Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma	Phase 1/Phase 2
Completed	`NCT00078858` - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Phase 1/Phase 2
Completed	`NCT00047203` - Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma	Phase 2
Active, not recruiting	`NCT03731832` - Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma	Phase 2
Completed	`NCT00003196` - Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma	N/A
Recruiting	`NCT03601624` - Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans	Phase 2
Terminated	`NCT01954784` - Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma	Phase 1
Recruiting	`NCT05020444` - TriPRIL CAR T Cells in Multiple Myeloma	Phase 1
Completed	`NCT01588015` - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	Phase 1
Recruiting	`NCT04302324` - A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab	Phase 2
Recruiting	`NCT06119685` - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers	Phase 1/Phase 2
Completed	`NCT00118170` - Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	Phase 1
Completed	`NCT00054353` - Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma	Phase 1/Phase 2